{"id":"hormonal-therapy-roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/","eras":[{"era":"1896-1980s","title":"Removing the hormone","description":"Beatson removed the ovaries of a woman with advanced breast cancer in 1896 and watched the tumour regress; Huggins showed in 1941 that castration controlled metastatic prostate cancer. Tamoxifen (1977), a receptor blocker taken as a pill, halved recurrence after breast surgery and became the first targeted cancer drug. GnRH analogues made castration reversible and chemical.","status":"historic","refs":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","status":"approved","tldr":"The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women."},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","status":"standard-of-care","tldr":"Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years."},{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","status":"standard-of-care","tldr":"Androgen deprivation lowers testosterone or blocks its receptor, and has been the foundation of prostate cancer treatment since 1941 (Nobel Prize 1966)."},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","status":"approved","tldr":"Monthly or 3-monthly injections that switch off the ovaries, letting premenopausal women use aromatase inhibitors and lowering recurrence in higher-risk cases."},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","status":"approved","tldr":"Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer."},{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","status":"approved","tldr":"The old antiandrogen pill used to block the testosterone flare from GnRH agonists and in combined androgen blockade; superseded by enzalutamide-class drugs."}],"trials":[],"papers":[]},{"era":"1990s-2010s","title":"Aromatase inhibitors, fulvestrant and ovarian suppression","description":"Aromatase inhibitors stopped oestrogen production in postmenopausal women and edged out tamoxifen in adjuvant trials; fulvestrant destroyed the receptor by injection. SOFT and TEXT showed that suppressing the ovaries and adding an aromatase inhibitor prevents more recurrences in young women than tamoxifen alone. Five to ten years of daily therapy became the norm, and adherence and side-effects became the limiting factor.","status":"historic","refs":[{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","status":"approved","tldr":"Daily pills that stop the body making oestrogen after menopause, the backbone of hormone therapy for most breast cancers."},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","status":"approved","tldr":"Exemestane is a steroidal aromatase inhibitor, the partner of everolimus and the agent tested with ovarian suppression in young women."},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","status":"approved","tldr":"Fulvestrant is a monthly intramuscular injection that degrades the oestrogen receptor rather than blocking it, the endocrine backbone paired with CDK4/6, PI3K and AKT inhibitors once aromatase inhibitors fail. Slow uptake and incomplete receptor degradation drove the search for oral degraders."},{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","status":"positive","tldr":"For younger women, shutting down the ovaries and adding an aromatase inhibitor prevents more recurrences than tamoxifen alone, with the largest gains in the highest-risk women."},{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","status":"emerging","tldr":"Hot flushes on tamoxifen or aromatase inhibitors are common and hormone replacement is off the table. Acupuncture reduced flushes in several randomised trials, in one about as well as the drug gabapentin and with fewer side effects, though sham-controlled results are mixed."},{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","status":"established","tldr":"Joint pain and stiffness are the main reason women stop aromatase-inhibitor tablets early. In a large randomised trial, twelve weeks of acupuncture reduced that pain more than sham needling or no treatment, and the benefit lasted after the sessions ended."}],"trials":[{"id":"soft-text","name":"SOFT & TEXT","route":"/trials/soft-text/","outcomes":[{"endpoint":"12-year disease-free survival (TEXT+SOFT)","primary":true,"unit":"%","arms":[{"name":"Exemestane + OFS","value":80.5},{"name":"Tamoxifen + OFS","value":75.9}],"hr":0.79,"ci":[0.7,0.9],"source":"https://ascopubs.org/doi/10.1200/JCO.22.01064"}],"setting":"Premenopausal HR+ early breast cancer: ovarian function suppression + exemestane vs + tamoxifen vs tamoxifen alone","enrolled":5738,"enrolledBasis":"registry"}],"papers":[]},{"era":"2011-2024","title":"Prostate cancer: earlier, deeper, combined","description":"Abiraterone and enzalutamide, then apalutamide and darolutamide, blocked the androgen pathway inside the tumour after castration stopped working, and were then moved to first metastatic diagnosis (LATITUDE, ARCHES). CHAARTED and STAMPEDE added docetaxel; ARASENS and PEACE-1 proved triplet therapy. EMBARK treated rising PSA after local therapy, and relugolix made testosterone suppression an oral pill. PSMAfore moved the PSMA radioligand ahead of chemotherapy.","status":"current","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","status":"approved","tldr":"Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis."},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","status":"approved","tldr":"Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-resistant disease, and fatigue, falls and memory problems are its main drawbacks."},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","status":"approved","tldr":"An AR blocker approved for prostate cancer that has spread and for high-risk disease before it shows on scans."},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","status":"approved","tldr":"Darolutamide is an AR blocker that barely enters the brain, so it causes fewer falls and cognitive side effects; it is approved with and without chemotherapy."},{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","status":"approved","tldr":"Relugolix is the first hormone-suppressing pill for prostate cancer, working within days and wearing off quickly when stopped."},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","status":"approved","tldr":"An injectable hormone blocker for prostate cancer that lowers testosterone within days without the initial surge caused by agonists."},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","status":"positive","tldr":"The first trial to show chemotherapy at the start of hormone therapy prolongs life in metastatic prostate cancer."},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","status":"positive","tldr":"STAMPEDE is the longest-running platform trial in oncology, and showed that both docetaxel and abiraterone extend life when started at first diagnosis of metastatic disease."},{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","status":"positive","tldr":"LATITUDE established abiraterone at first metastatic diagnosis for high-risk disease."},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","status":"positive","tldr":"Brought enzalutamide into first-line metastatic treatment, with an overall survival benefit confirmed in 2021."},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","status":"positive","tldr":"Proved 'triplet therapy': adding darolutamide to hormone therapy plus chemotherapy reduces death by a third."},{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","status":"positive","tldr":"PEACE-1 is the European triplet trial: abiraterone added to hormone therapy and docetaxel improves survival, especially in high-volume disease."},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","status":"positive","tldr":"Showed that treating a fast-rising PSA after surgery or radiation with enzalutamide delays spread."},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","status":"positive","tldr":"PSMAfore moved Pluvicto before chemotherapy in prostate cancer."}],"trials":[{"id":"chaarted","name":"CHAARTED (E3805)","route":"/trials/chaarted/","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"ADT + docetaxel","n":397,"value":57.6},{"name":"ADT alone","n":393,"value":44}],"hr":0.61,"ci":[0.47,0.8],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1503747"},{"endpoint":"Overall survival (median)","primary":true,"unit":"months","arms":[{"name":"Androgen deprivation with docetaxel","value":57.6},{"name":"Androgen deprivation alone","value":44}],"hr":0.61,"ci":[0.47,0.8],"p":"<0.001","source":"https://doi.org/10.1056/NEJMoa1503747"},{"endpoint":"Time to biochemical, symptomatic or radiographic progression (median)","unit":"months","arms":[{"name":"Androgen deprivation with docetaxel","value":20.2},{"name":"Androgen deprivation alone","value":11.7}],"hr":0.61,"ci":[0.51,0.72],"p":"<0.001","source":"https://doi.org/10.1056/NEJMoa1503747"}],"setting":"Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT","enrolled":790,"enrolledBasis":"registry"},{"id":"stampede","name":"STAMPEDE","route":"/trials/stampede/","outcomes":[{"endpoint":"Overall survival, abiraterone arm (M1 subgroup)","primary":true,"unit":"%","arms":[{"name":"ADT + abiraterone","note":"6-year OS 60%"},{"name":"ADT alone","note":"6-year OS 45%"}],"hr":0.6,"ci":[0.5,0.71],"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltext"},{"endpoint":"Overall survival, docetaxel arm (M1)","unit":"months","arms":[{"name":"ADT + docetaxel","value":60},{"name":"ADT alone","value":45}],"hr":0.76,"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext"},{"endpoint":"Overall survival, abiraterone comparison","unit":"deaths","arms":[{"name":"Androgen deprivation with abiraterone and prednisolone","n":960,"value":184},{"name":"Androgen deprivation alone","n":957,"value":262}],"hr":0.63,"ci":[0.52,0.76],"p":"<0.001","source":"https://doi.org/10.1056/NEJMoa1702900"},{"endpoint":"Metastasis-free survival at 6 years, high-risk non-metastatic comparison","unit":"%","arms":[{"name":"Androgen deprivation with 2 years of abiraterone","value":82},{"name":"Androgen deprivation alone","value":69}],"hr":0.53,"ci":[0.44,0.64],"p":"<0.0001","source":"https://doi.org/10.1016/S0140-6736(21)02437-5"},{"endpoint":"Overall survival, prostate radiotherapy comparison","arms":[{"name":"Standard of care with prostate radiotherapy","n":1032},{"name":"Standard of care","n":1029}],"hr":0.92,"ci":[0.8,1.06],"p":"0.266","source":"https://doi.org/10.1016/S0140-6736(18)32486-3"},{"endpoint":"Overall survival (median), metformin comparison","unit":"months","arms":[{"name":"Standard of care with metformin","n":936,"value":67.4},{"name":"Standard of care","n":938,"value":61.8}],"hr":0.91,"ci":[0.8,1.03],"p":"0.15","source":"https://doi.org/10.1016/S1470-2045(25)00231-1"}],"setting":"Multi-arm multi-stage platform in men starting long-term hormone therapy for high-risk locally advanced or metastatic prostate cancer: docetaxel, zoledronic acid, celecoxib, abiraterone, radiotherapy to the prostate, abiraterone with enzalutamide, metformin and transdermal oestradiol added to ADT and compared with ADT alone","enrolled":11992,"enrolledBasis":"registry"},{"id":"latitude","name":"LATITUDE","route":"/trials/latitude/","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"ADT + abiraterone","n":597,"value":53.3},{"name":"ADT + placebo","n":602,"value":36.5}],"hr":0.66,"ci":[0.56,0.78],"p":"<0.0001","source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30082-8/fulltext"}],"setting":"High-risk de novo metastatic hormone-sensitive prostate cancer: ADT + abiraterone vs ADT","enrolled":1209,"enrolledBasis":"registry"},{"id":"arches","name":"ARCHES","route":"/trials/arches/","outcomes":[{"endpoint":"Radiographic progression-free survival","primary":true,"unit":"months","arms":[{"name":"ADT + enzalutamide","n":574,"note":"Median not reached"},{"name":"ADT + placebo","n":576,"value":19}],"hr":0.39,"ci":[0.3,0.5],"p":"<0.001","source":"https://ascopubs.org/doi/10.1200/JCO.19.00799"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"ADT + enzalutamide","note":"Medians not reached at the final analysis"},{"name":"ADT + placebo"}],"hr":0.66,"ci":[0.53,0.81],"source":"https://ascopubs.org/doi/10.1200/JCO.22.00193"}],"setting":"Metastatic hormone-sensitive prostate cancer: ADT + enzalutamide vs ADT","enrolled":1150,"enrolledBasis":"registry"},{"id":"arasens","name":"ARASENS","route":"/trials/arasens/","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Darolutamide + ADT + docetaxel","n":651,"note":"Median not reached"},{"name":"Placebo + ADT + docetaxel","n":655,"value":48.9}],"hr":0.68,"ci":[0.57,0.8],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2119115"}],"setting":"Metastatic hormone-sensitive prostate cancer: ADT + docetaxel + darolutamide vs ADT + docetaxel","enrolled":1306,"enrolledBasis":"registry"},{"id":"peace-1","name":"PEACE-1","route":"/trials/peace-1/","outcomes":[{"endpoint":"Overall survival, abiraterone vs no abiraterone (with ADT + docetaxel)","primary":true,"unit":"months","arms":[{"name":"Abiraterone + ADT + docetaxel","value":66},{"name":"ADT + docetaxel","value":52}],"hr":0.75,"ci":[0.59,0.95],"p":"0.017","source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltext"}],"setting":"De novo metastatic hormone-sensitive prostate cancer: ADT + docetaxel ± abiraterone ± prostate radiotherapy (2×2 factorial)","enrolled":1173,"enrolledBasis":"registry"},{"id":"embark","name":"EMBARK","route":"/trials/embark/","outcomes":[{"endpoint":"Metastasis-free survival, enzalutamide + leuprolide vs leuprolide","primary":true,"unit":"%","arms":[{"name":"Enzalutamide + leuprolide, 5-year MFS","n":355,"value":87.3},{"name":"Leuprolide alone, 5-year MFS","n":358,"value":71.4}],"hr":0.42,"ci":[0.3,0.61],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2303974"}],"setting":"High-risk biochemical recurrence (PSA doubling time ≤9 months) after local therapy: enzalutamide + leuprolide, enzalutamide alone, or leuprolide alone","enrolled":1068,"enrolledBasis":"registry"},{"id":"psmafore","name":"PSMAfore","route":"/trials/psmafore/","outcomes":[{"endpoint":"Radiographic progression-free survival","primary":true,"unit":"months","arms":[{"name":"177Lu-PSMA-617","n":234,"value":12},{"name":"ARPI switch","n":234,"value":5.6}],"hr":0.41,"ci":[0.29,0.56],"p":"<0.0001","source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01653-2/fulltext"},{"endpoint":"Overall survival (crossover-adjusted)","unit":"months","arms":[{"name":"177Lu-PSMA-617","note":"Unadjusted OS HR 0.98 with 84% crossover from control"},{"name":"ARPI switch"}],"hr":0.59,"source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01653-2/fulltext"}],"setting":"PSMA+ mCRPC after one ARPI, taxane-naive: 177Lu-PSMA-617 vs ARPI switch","enrolled":469,"enrolledBasis":"registry"}],"papers":[]},{"era":"2015-2026","title":"Breast cancer: CDK4/6 inhibitors and the pathway partners","description":"Palbociclib (2015), ribociclib and abemaciclib roughly doubled progression-free time when added to endocrine therapy, and ribociclib extended survival (MONALEESA-2). monarchE and NATALEE brought the class into the adjuvant setting; PALLAS and PENELOPE-B showed it does not work for every drug. Alpelisib (SOLAR-1), capivasertib (CAPItello-291), inavolisib and gedatolisib target the PI3K-AKT-mTOR escape pathway in tumours that carry the mutations, at the cost of high blood sugar and rash.","status":"current","refs":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","status":"approved","tldr":"Pills that stop the cell-division engine, added to hormone therapy for the most common type of breast cancer."},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","status":"approved","tldr":"Palbociclib was the first CDK4/6 inhibitor (2015), and in 2026 became the first approved as maintenance in HER2-positive, hormone-positive breast cancer."},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","status":"approved","tldr":"Ribociclib is the CDK4/6 inhibitor with the most consistent survival benefit, approved for a broad population of early breast cancer patients since 2024."},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","status":"approved","tldr":"Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer."},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","status":"approved","tldr":"Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials."},{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","status":"mixed","tldr":"The trial that made palbociclib the first CDK4/6 inhibitor in routine use. It doubled progression-free time but did not extend life."},{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","status":"positive","tldr":"The first CDK4/6 inhibitor trial to show that adding the pill to hormone therapy makes women live longer, by about a year."},{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","status":"positive","tldr":"Abemaciclib roughly doubled the time to progression when added to an aromatase inhibitor; the survival gain of about 13 months narrowly missed statistical significance."},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","status":"positive","tldr":"The first CDK4/6 inhibitor to reduce recurrence after surgery in high-risk hormone-positive breast cancer."},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","status":"positive","tldr":"Extended CDK4/6 inhibitors to a broad group of early hormone-positive breast cancer patients, including node-negative."},{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","status":"negative","tldr":"Two large trials found that adding palbociclib after surgery does not prevent recurrence, even though the same drug helps in metastatic disease."},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","status":"approved","tldr":"Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs are displacing it."},{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","status":"positive","tldr":"The first trial to show a PI3K inhibitor helps in breast cancers carrying a PIK3CA mutation, at the cost of high blood sugar and rash."},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","status":"approved","tldr":"Capivasertib (Truqap) is the first AKT inhibitor, for breast cancer with PI3K-pathway mutations and, since 2026, for prostate cancer with PTEN loss."},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","status":"positive","tldr":"Adding the AKT inhibitor capivasertib to fulvestrant doubled progression-free time, especially in tumours with PI3K-pathway mutations."},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","status":"approved","tldr":"Inavolisib is a PI3K drug that also destroys the mutant protein, approved in 2024 with palbociclib and fulvestrant for PIK3CA-mutant breast cancer."},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","status":"approved","tldr":"An intravenous drug that blocks the whole PI3K/mTOR pathway, approved in July 2026 for hormone-positive breast cancer."},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","status":"approved","tldr":"An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant."}],"trials":[{"id":"paloma-2","name":"PALOMA-2","route":"/trials/paloma-2/","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Palbociclib + letrozole","n":444,"value":27.6},{"name":"Placebo + letrozole","n":222,"value":14.5}],"hr":0.56,"ci":[0.46,0.69],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1607303"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Palbociclib + letrozole","value":53.9},{"name":"Placebo + letrozole","value":51.2}],"hr":0.96,"ci":[0.78,1.18],"source":"https://doi.org/10.1056/NEJMoa1607303"}],"setting":"First-line postmenopausal HR+/HER2- advanced breast cancer: palbociclib + letrozole vs placebo + letrozole","enrolled":666,"enrolledBasis":"registry"},{"id":"monaleesa-2","name":"MONALEESA-2","route":"/trials/monaleesa-2/","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Ribociclib + letrozole","n":334,"value":25.3},{"name":"Placebo + letrozole","n":334,"value":16}],"hr":0.57,"ci":[0.46,0.7],"source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1609709"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Ribociclib + letrozole","n":334,"value":63.9},{"name":"Placebo + letrozole","n":334,"value":51.4}],"hr":0.76,"ci":[0.63,0.93],"p":"0.004","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2114663"}],"setting":"First-line postmenopausal HR+/HER2- advanced breast cancer: ribociclib + letrozole vs placebo + letrozole","enrolled":668,"enrolledBasis":"registry"},{"id":"monarch-3","name":"MONARCH 3","route":"/trials/monarch-3/","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Abemaciclib + NSAI","n":328,"value":28.2},{"name":"Placebo + NSAI","n":165,"value":14.8}],"hr":0.54,"ci":[0.42,0.7],"source":"https://ascopubs.org/doi/10.1200/JCO.2017.75.6155"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Abemaciclib + NSAI","value":66.8},{"name":"Placebo + NSAI","value":53.7}],"hr":0.8,"ci":[0.62,1.03],"p":"0.066","source":"https://doi.org/10.1200/JCO.2017.75.6155"}],"setting":"First-line postmenopausal HR+/HER2- advanced breast cancer: abemaciclib + NSAI vs placebo + NSAI","enrolled":493,"enrolledBasis":"registry"},{"id":"monarche","name":"monarchE","route":"/trials/monarche/","outcomes":[{"endpoint":"Invasive disease-free survival at 2 years","primary":true,"unit":"%","arms":[{"name":"Abemaciclib + endocrine therapy","n":2808,"value":92.2},{"name":"Endocrine therapy alone","n":2829,"value":88.7}],"hr":0.75,"ci":[0.6,0.93],"p":"0.01","source":"https://ascopubs.org/doi/10.1200/JCO.20.02514"},{"endpoint":"Invasive disease-free survival at 5 years","unit":"%","arms":[{"name":"Abemaciclib + endocrine therapy","value":83.6},{"name":"Endocrine therapy alone","value":76}],"hr":0.68,"ci":[0.6,0.77],"source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00525-2/fulltext"},{"endpoint":"Distant relapse-free survival at 5 years","unit":"%","arms":[{"name":"Abemaciclib + endocrine therapy","value":86},{"name":"Endocrine therapy alone","value":79.2}],"hr":0.675,"source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00525-2/fulltext"}],"setting":"Adjuvant abemaciclib 2 years + endocrine therapy in high-risk node-positive HR+/HER2- breast cancer","enrolled":5637,"enrolledBasis":"registry"},{"id":"natalee","name":"NATALEE","route":"/trials/natalee/","outcomes":[{"endpoint":"Invasive disease-free survival at 3 years","primary":true,"unit":"%","arms":[{"name":"Ribociclib + NSAI","n":2549,"value":90.4},{"name":"NSAI alone","n":2552,"value":87.1}],"hr":0.75,"ci":[0.62,0.91],"p":"0.003","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2305488"},{"endpoint":"Invasive disease-free survival at 4 years","unit":"%","arms":[{"name":"Ribociclib + NSAI","value":88.5},{"name":"NSAI alone","value":83.6}],"hr":0.715,"ci":[0.609,0.84],"source":"https://clinicaltrials.gov/study/NCT03701334"}],"setting":"Adjuvant ribociclib 3 years + endocrine therapy in stage II-III HR+/HER2- breast cancer","enrolled":5101,"enrolledBasis":"registry"},{"id":"pallas-penelope-b","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","outcomes":[{"endpoint":"4-year invasive disease-free survival (PALLAS)","primary":true,"unit":"%","arms":[{"name":"Palbociclib + ET","value":84.2},{"name":"ET alone","value":84.5}],"hr":0.96,"ci":[0.81,1.14],"source":"https://ascopost.com/issues/december-25-2021/final-analysis-of-pallas-trial-no-benefit-of-adjuvant-palbociclib-plus-endocrine-therapy-in-early-breast-cancer/"}],"setting":"Adjuvant palbociclib + endocrine therapy in HR+/HER2- early breast cancer (PALLAS, 2 years; PENELOPE-B, 1 year after residual disease)","enrolled":6862,"enrolledBasis":"registry"},{"id":"solar-1","name":"SOLAR-1","route":"/trials/solar-1/","outcomes":[{"endpoint":"Progression-free survival (PIK3CA-mutant)","primary":true,"unit":"months","arms":[{"name":"Alpelisib + fulvestrant","n":169,"value":11},{"name":"Placebo + fulvestrant","n":172,"value":5.7}],"hr":0.65,"ci":[0.5,0.85],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1813904"}],"setting":"HR+/HER2- advanced breast cancer after aromatase inhibitor: alpelisib + fulvestrant vs placebo + fulvestrant, by PIK3CA status","enrolled":572,"enrolledBasis":"registry"},{"id":"capitello-291","name":"CAPItello-291","route":"/trials/capitello-291/","outcomes":[{"endpoint":"Progression-free survival (overall)","primary":true,"unit":"months","arms":[{"name":"Capivasertib + fulvestrant","n":355,"value":7.2},{"name":"Placebo + fulvestrant","n":353,"value":3.6}],"hr":0.6,"ci":[0.51,0.71],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2214131"},{"endpoint":"Progression-free survival (AKT-pathway-altered)","primary":true,"unit":"months","arms":[{"name":"Capivasertib + fulvestrant","n":155,"value":7.3},{"name":"Placebo + fulvestrant","n":134,"value":3.1}],"hr":0.5,"ci":[0.38,0.65],"p":"<0.001","source":"https://doi.org/10.1056/NEJMoa2214131"}],"setting":"HR+/HER2- advanced breast cancer after aromatase inhibitor (± CDK4/6): capivasertib + fulvestrant vs placebo + fulvestrant","enrolled":708,"enrolledNote":"ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients.","enrolledBasis":"randomised"}],"papers":[]},{"era":"2023-2026","title":"Degrading the receptor, switching on a blood test","description":"ESR1 mutations let the receptor work without oestrogen, defeating aromatase inhibitors. Oral degraders remove the receptor itself: elacestrant (2023, EMERALD), imlunestrant (2025, EMBER-3) and camizestrant (September 2026). Vepdegestrant, approved in 2026 after VERITAC-2, is the first PROTAC in any disease. SERENA-6 changed the rules of engagement: it switched to camizestrant when an ESR1 mutation appeared in blood, before the scan showed progression, and delayed progression by doing so. FES PET shows which deposits still carry the receptor.","status":"current","refs":[{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","status":"approved","tldr":"Elacestrant was the first oral oestrogen-receptor degrader (2023), for ESR1-mutant breast cancer detected by blood test."},{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","status":"positive","tldr":"The first oral oestrogen-receptor degrader to beat standard hormone therapy, with the benefit concentrated in tumours carrying ESR1 mutations."},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","status":"approved","tldr":"Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation."},{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","status":"positive","tldr":"An oral SERD that works alone in ESR1-mutant tumours and, combined with abemaciclib, doubles progression-free time in everyone regardless of mutation."},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","status":"approved","tldr":"Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows."},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","status":"positive","tldr":"The first trial to change treatment because of a blood test rather than a scan: switching to camizestrant when an ESR1 mutation appeared in the blood delayed progression by seven months."},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","status":"approved","tldr":"Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations."},{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","status":"mixed","tldr":"The trial that got the first PROTAC approved, with benefit only in tumours with ESR1 mutations."},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","status":"approved","tldr":"Instead of blocking a protein, these drugs tag it for the cell's own garbage disposal, removing it entirely."},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","status":"standard-of-care","tldr":"A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour."},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","status":"approved","tldr":"A PET scan that shows which breast cancer deposits still have oestrogen receptors, helping decide whether hormone therapy will work when biopsy is impractical."}],"trials":[{"id":"emerald","name":"EMERALD","route":"/trials/emerald/","outcomes":[{"endpoint":"Progression-free survival (ESR1-mutant)","primary":true,"unit":"months","arms":[{"name":"Elacestrant","n":115,"value":3.8},{"name":"Standard endocrine therapy","n":113,"value":1.9}],"hr":0.55,"ci":[0.39,0.77],"p":"0.0005","source":"https://ascopubs.org/doi/10.1200/JCO.22.00338"},{"endpoint":"Progression-free survival (all patients)","primary":true,"unit":"months","arms":[{"name":"Elacestrant","n":239,"value":2.8},{"name":"Standard endocrine therapy","n":239,"value":1.9}],"hr":0.7,"ci":[0.55,0.88],"p":"0.002","source":"https://doi.org/10.1200/JCO.22.00338"}],"setting":"ER+/HER2- advanced breast cancer after 1-2 endocrine lines including a CDK4/6 inhibitor: elacestrant vs standard endocrine therapy","enrolled":478,"enrolledBasis":"registry"},{"id":"ember-3","name":"EMBER-3","route":"/trials/ember-3/","outcomes":[{"endpoint":"Progression-free survival, ESR1-mutant (imlunestrant vs standard ET)","primary":true,"unit":"months","arms":[{"name":"Imlunestrant","value":5.5},{"name":"Standard endocrine therapy","value":3.8}],"hr":0.62,"ci":[0.46,0.82],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2410858"},{"endpoint":"Progression-free survival (imlunestrant + abemaciclib vs imlunestrant)","primary":true,"unit":"months","arms":[{"name":"Imlunestrant + abemaciclib","n":213,"value":10.9},{"name":"Imlunestrant","n":213,"value":5.5}],"hr":0.59,"ci":[0.46,0.75],"p":"<0.001","source":"https://www.annalsofoncology.org/article/S0923-7534(25)06289-1/fulltext"},{"endpoint":"Overall survival, ESR1-mutant (imlunestrant vs standard ET), updated","unit":"months","arms":[{"name":"Imlunestrant","value":34.5},{"name":"Standard endocrine therapy","value":23.1}],"source":"https://www.mskcc.org/clinical-updates/sabcs-2025-news-updated-ember-3-efficacy-results-for-imlunestrant-with-or-without-abemaciclib-in-er-her2-advanced-breast"}],"setting":"ER+/HER2- advanced breast cancer after ≥1 endocrine line: imlunestrant vs standard endocrine therapy, and imlunestrant + abemaciclib vs imlunestrant","enrolled":874,"enrolledBasis":"registry"},{"id":"serena-6","name":"SERENA-6","route":"/trials/serena-6/","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Switch to camizestrant + CDK4/6","n":157,"value":16},{"name":"Continue AI + CDK4/6","n":158,"value":9.2}],"hr":0.44,"ci":[0.31,0.6],"p":"<0.0001","source":"https://www.onclive.com/view/fda-approves-camizestrant-plus-a-cdk4-6-inhibitor-for-emergent-esr1-mutated-hr-her2-advanced-breast-cancer"}],"setting":"First-line HR+/HER2- advanced breast cancer on AI + CDK4/6 with an ESR1 mutation detected in ctDNA before radiographic progression: switch to camizestrant + CDK4/6 vs continue AI + CDK4/6","enrolled":315,"enrolledBasis":"registry"},{"id":"veritac-2","name":"VERITAC-2","route":"/trials/veritac-2/","outcomes":[{"endpoint":"Progression-free survival, ESR1-mutant (BICR)","primary":true,"unit":"months","arms":[{"name":"Vepdegestrant","n":136,"value":5},{"name":"Fulvestrant","n":134,"value":2.1}],"hr":0.57,"ci":[0.42,0.77],"p":"<0.001","source":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1000"},{"endpoint":"Progression-free survival, ITT","primary":true,"unit":"months","arms":[{"name":"Vepdegestrant","n":313,"value":3.7,"note":"Not significant"},{"name":"Fulvestrant","n":311,"value":3.6}],"hr":0.83,"ci":[0.68,1.02],"source":"https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1000"}],"setting":"ER+/HER2- advanced breast cancer after CDK4/6 and endocrine therapy: vepdegestrant vs fulvestrant","enrolled":624,"enrolledBasis":"registry"}],"papers":[]},{"era":"2026-2030","title":"Into the adjuvant setting and around the next resistance","description":"lidERA is the first oral degrader to reduce recurrence after surgery; CAMBRIA-1 and CAMBRIA-2 test whether degraders should replace today's adjuvant pills outright, while persevERA showed they do not automatically win first-line. postMONARCH and evERA map what to do after CDK4/6 failure. Atirmociclib blocks CDK4 only, to keep the benefit without the low blood counts. In prostate cancer, PARP inhibitors (PROpel, TALAPRO-2, MAGNITUDE) work in tumours with DNA-repair defects, capivasertib in PTEN-deficient disease (CAPItello-281), and the EZH2 inhibitor mevrometostat aims to re-sensitise tumours to enzalutamide (MEVPRO-1).","status":"emerging","refs":[{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","status":"positive","tldr":"The first oral SERD to reduce recurrence after surgery, by about 30%, compared with today's hormone pills."},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","status":"phase-3","tldr":"Giredestrant is Roche's oral SERD: it failed to beat an aromatase inhibitor in first-line metastatic disease but succeeded after surgery and after CDK4/6 failure."},{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","status":"active","tldr":"CAMBRIA-1 and CAMBRIA-2 are two adjuvant trials enrolling close to 10,000 women with early hormone-receptor-positive breast cancer to test whether the oral oestrogen-receptor degrader camizestrant should replace today's adjuvant hormone tablets, either as a switch after two to five years or from the start. Results are awaited."},{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","status":"negative","tldr":"An oral SERD did not beat the aromatase inhibitor in first-line treatment when both were combined with palbociclib. Oral SERDs earn their place after resistance, not before it."},{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","status":"positive","tldr":"Continuing CDK4/6 blockade with a different drug after the first one fails gives a small but real benefit."},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","status":"positive","tldr":"In evERA, pairing an oral SERD with everolimus after CDK4/6 failure delayed progression by more than three months, and by four and a half months in ESR1-mutant tumours."},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","status":"phase-3","tldr":"A next-generation pill that blocks only CDK4, not CDK6, to keep the benefit of today's drugs without the low blood counts."},{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","status":"positive","tldr":"In FOURLIGHT-1, a CDK4-only inhibitor designed to avoid the low blood counts of current CDK4/6 drugs improved progression-free survival in second line."},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","status":"positive","tldr":"Showed PARP inhibitor plus abiraterone delays progression in first-line mCRPC, with the largest benefit in BRCA-mutant men."},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","status":"positive","tldr":"The PARP-plus-hormone combination that eventually showed an overall survival benefit, in 2024-25."},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","status":"mixed","tldr":"PARP inhibitor plus abiraterone helped men with BRCA mutations and did nothing for those without, settling a debate."},{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","status":"positive","tldr":"CAPItello-281 delivered the first AKT inhibitor success in prostate cancer, for the ~25% of men whose tumours have lost PTEN on the trial's own immunohistochemistry cut-off."},{"id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","status":"phase-3","tldr":"An epigenetic drug that may re-sensitise prostate cancer to hormone therapy, in three phase 3 trials with enzalutamide."},{"id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","status":"active","tldr":"MEVPRO-1 is the phase 3 trial of the first EZH2 inhibitor combination in prostate cancer."}],"trials":[{"id":"lidera","name":"lidERA","route":"/trials/lidera/","outcomes":[{"endpoint":"Invasive disease-free survival","primary":true,"arms":[{"name":"Giredestrant","note":"30% reduction in iDFS events vs standard ET"},{"name":"Standard endocrine therapy"}],"hr":0.7,"source":"https://www.roche.com/media/releases/med-cor-2026-05-19"}],"setting":"Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years","enrolled":4170,"enrolledBasis":"registry"},{"id":"persevera","name":"persevERA","route":"/trials/persevera/","outcomes":[{"endpoint":"Progression-free survival (investigator)","primary":true,"unit":"months","arms":[{"name":"Giredestrant + palbociclib","value":33.1},{"name":"Letrozole + palbociclib","value":28.2}],"source":"https://www.roche.com/media/releases/med-cor-2026-03-09"}],"setting":"First-line ER+/HER2- advanced breast cancer: giredestrant + palbociclib vs letrozole + palbociclib","enrolled":992,"enrolledBasis":"registry"},{"id":"postmonarch","name":"postMONARCH","route":"/trials/postmonarch/","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Abemaciclib + fulvestrant","n":182,"value":6},{"name":"Placebo + fulvestrant","n":186,"value":5.3}],"hr":0.73,"ci":[0.57,0.95],"p":"0.017","source":"https://ascopubs.org/doi/10.1200/JCO-24-02086"}],"setting":"HR+/HER2- advanced breast cancer after progression on CDK4/6 + endocrine therapy: abemaciclib + fulvestrant vs placebo + fulvestrant","enrolled":368,"enrolledBasis":"registry"},{"id":"evera","name":"evERA","route":"/trials/evera/","outcomes":[{"endpoint":"Progression-free survival (ITT)","primary":true,"unit":"months","arms":[{"name":"Giredestrant + everolimus","value":8.77},{"name":"Standard ET + everolimus","value":5.49}],"hr":0.56,"ci":[0.44,0.71],"p":"<0.0001","source":"https://www.roche.com/media/releases/med-cor-2025-10-18"},{"endpoint":"Progression-free survival (ESR1-mutant)","primary":true,"unit":"months","arms":[{"name":"Giredestrant + everolimus","value":9.99},{"name":"Standard ET + everolimus","value":5.45}],"hr":0.38,"ci":[0.27,0.54],"p":"<0.0001"}],"setting":"ER+/HER2- advanced breast cancer after CDK4/6 inhibitor: giredestrant + everolimus vs standard endocrine therapy + everolimus","enrolled":320,"enrolledNote":"ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication.","enrolledBasis":"randomised"},{"id":"fourlight-1","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","outcomes":[{"endpoint":"Progression-free survival (investigator-assessed)","primary":true,"unit":"months","arms":[{"name":"Atirmociclib + fulvestrant","note":"Randomised phase 2, post-CDK4/6 inhibitor; medians pending presentation (topline 17 March 2026)"},{"name":"Fulvestrant, or everolimus + exemestane"}],"hr":0.6,"ci":[0.44,0.825],"p":"0.0007","source":"https://www.cancernetwork.com/view/atirmociclib-fulvestrant-improves-pfs-in-hr-her2-breast-cancer"}],"setting":"HR+/HER2- advanced breast cancer after CDK4/6 inhibitor: atirmociclib + fulvestrant vs fulvestrant","enrolled":333,"enrolledBasis":"registry"},{"id":"propel","name":"PROpel","route":"/trials/propel/","outcomes":[{"endpoint":"Radiographic progression-free survival (investigator), all comers","primary":true,"unit":"months","arms":[{"name":"Olaparib + abiraterone","n":399,"value":24.8},{"name":"Placebo + abiraterone","n":397,"value":16.6}],"hr":0.66,"ci":[0.54,0.81],"p":"<0.001","source":"https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043"},{"endpoint":"Overall survival, all comers","unit":"months","arms":[{"name":"Olaparib + abiraterone","value":42.1,"note":"Not significant; larger effect in BRCA-mutant"},{"name":"Placebo + abiraterone","value":34.7}],"hr":0.81,"ci":[0.67,1],"source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-9/fulltext"}],"setting":"First-line mCRPC, all-comers: abiraterone + olaparib vs abiraterone + placebo","enrolled":796,"enrolledNote":"ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis.","enrolledBasis":"randomised"},{"id":"talapro-2","name":"TALAPRO-2","route":"/trials/talapro-2/","outcomes":[{"endpoint":"Radiographic progression-free survival, all comers","primary":true,"unit":"months","arms":[{"name":"Talazoparib + enzalutamide","n":402,"note":"Median not reached"},{"name":"Placebo + enzalutamide","n":403,"value":21.9}],"hr":0.63,"ci":[0.51,0.78],"p":"<0.0001","source":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01055-3/fulltext"},{"endpoint":"Overall survival, all comers (final)","unit":"months","arms":[{"name":"Talazoparib + enzalutamide","value":45.8},{"name":"Placebo + enzalutamide","value":37}],"hr":0.8,"ci":[0.66,0.96],"p":"0.016","source":"https://clinicaltrials.gov/study/NCT03395197"}],"setting":"First-line mCRPC: enzalutamide + talazoparib vs enzalutamide + placebo (all-comers and HRR-mutant cohorts)","enrolled":805,"enrolledNote":"ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo).","enrolledBasis":"randomised"},{"id":"magnitude","name":"MAGNITUDE","route":"/trials/magnitude/","outcomes":[{"endpoint":"Radiographic progression-free survival, BRCA1/2 subgroup","primary":true,"unit":"months","arms":[{"name":"Niraparib + abiraterone","n":113,"value":16.6},{"name":"Placebo + abiraterone","n":112,"value":10.9}],"hr":0.53,"ci":[0.36,0.79],"p":"0.001","source":"https://ascopubs.org/doi/10.1200/JCO.22.01649"}],"setting":"First-line mCRPC: abiraterone + niraparib vs abiraterone + placebo, HRR-mutant and HRR-negative cohorts","enrolled":423,"enrolledNote":"ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort.","enrolledBasis":"randomised"},{"id":"capitello-281","name":"CAPItello-281","route":"/trials/capitello-281/","outcomes":[{"endpoint":"Radiographic progression-free survival, PTEN-deficient mHSPC","primary":true,"unit":"months","arms":[{"name":"Capivasertib + abiraterone + ADT","value":40},{"name":"Placebo + abiraterone + ADT","value":31.7}],"hr":0.81,"ci":[0.68,0.96],"p":"0.017","source":"https://clinicaltrials.gov/study/NCT04493853"}],"setting":"De novo metastatic hormone-sensitive prostate cancer with PTEN deficiency: abiraterone + capivasertib vs abiraterone + placebo","enrolled":1012,"enrolledBasis":"registry"}],"papers":[]},{"era":"2030+","title":"Living well through a decade of therapy","description":"If resistance can be anticipated from blood, therapy could be sequenced or given intermittently to keep the sensitive clone dominant, an approach being tested in lung cancer and proposed for hormone-driven disease. The Breast Cancer Index already asks who benefits from extending therapy beyond five years. The bigger gains may be in staying on treatment: acupuncture for hot flushes and joint pain, cardiometabolic screening for men on long-term androgen deprivation, and low-dose tamoxifen for prevention prescribed outside the oncology clinic.","status":"speculative","refs":[{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/","status":"established","tldr":"The only test designed to tell a woman who has finished five years of hormone therapy whether another five years is worth the side effects."},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","tldr":"Use tumour DNA in the blood as the signal to pause and restart a lung cancer pill, keeping the tumour in check while slowing the rise of resistant cells."},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","tldr":"The dose needed to shrink a tumour may be higher than the dose needed to keep it from growing back. Trials that lower the dose once a response is achieved could reduce long-term side effects without losing control."},{"id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","tldr":"Hormone-blocking treatments for prostate and breast cancer, taken for years, raise the risk of diabetes, heart disease and bone fractures. Survivors on these drugs should get the same preventive care as diabetics."},{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/","status":"established","tldr":"Cardio-oncology builds heart risk assessment, monitoring and prevention into cancer care so patients can finish curative treatment without trading cancer for heart failure. It targets anthracycline and trastuzumab damage, checkpoint-inhibitor myocarditis and radiation heart disease using echocardiography, troponin tests and protective drugs; specialist clinics are concentrated in large centres."},{"id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","tldr":"A 5 mg tamoxifen dose halves breast cancer recurrence after precancer with far fewer side effects than the full dose. Almost nobody is prescribed it. Change who can prescribe."}],"trials":[],"papers":[]},{"era":"What sets the pace","title":"Resistance, price and tolerability","description":"Every hormonal agent eventually meets resistance, and the biology of the next escape (ESR1, PI3K, AR splice variants) decides which drug comes next. Multi-year combination therapy is priced per month, so cost compounds; shorter-course and de-escalation trials exist only when public funders run them. And the side-effects that make people stop a drug they should take for years are still measured less carefully than the effects on the tumour.","status":"current","refs":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","tldr":"Nearly every targeted therapy stops working within months to a few years as the tumour adapts."},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","tldr":"New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt."},{"id":"idea-cost-shorter-course-trials","kind":"idea","name":"Fund trials that test shorter courses of the most expensive adjuvant drugs","route":"/ideas/idea-cost-shorter-course-trials/","tldr":"The PERSEPHONE trial showed six months of trastuzumab after surgery is as good as twelve, halving the drug cost; no company will run such trials, so public funders and charities must."},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","tldr":"Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated."},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","tldr":"Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab."}],"trials":[],"papers":[]}],"watch":[]}